Vijay G Sankaran [1] [2] [3] & Mitchell J Weiss 4 Anemia is a major source of morbidity and mortality worldwide. Here we review recent insights into how red blood cells (RBCs) are produced, the pathogenic mechanisms underlying various forms of anemia, and novel therapies derived from these findings. It is likely that these new insights, mainly arising from basic scientific studies, will contribute immensely to both the understanding of frequently debilitating forms of anemia and the ability to treat affected patients. Major worldwide diseases that are likely to benefit from new advances include the hemoglobinopathies (β-thalassemia and sickle cell disease); rare genetic disorders of RBC production; and anemias associated with chronic kidney disease, inflammation, and cancer. Promising new approaches to treatment include drugs that target recently defined pathways in RBC production, iron metabolism, and fetal globin-family gene expression, as well as gene therapies that use improved viral vectors and newly developed genome editing technologies.
Anemia, defined as a decreased quantity of circulating RBCs (erythrocytes), is a major source of morbidity and mortality worldwide. Recent epidemiological studies suggest that one-third of the world's population is affected 1 . Much of this burden is due to nutritional, infectious, and systemic etiologies, including iron deficiency, malaria, schistosomiasis, and chronic kidney disease 1 . Genetic disorders of hemoglobin (Hb), including sickle cell disease (SCD) and thalassemia, are also common causes of clinically significant anemia, particularly among children 2 .
Recent studies have produced important insights into the molecular mechanisms of normal RBC homeostasis and how these processes go awry in human disease. These efforts have generated novel therapeutic approaches and several new drugs that are now being examined in clinical trials. Here we review these studies, emphasizing how investigation of the basic biology of anemia can generate new findings of clinical relevance.
Normal erythropoiesis and the pathophysiology of common anemias Healthy human adults produce approximately 2 million RBCs every second through a coordinated process that begins with multipotent hematopoietic stem and progenitor cells (HSPCs) 3, 4 . One model for this developmental pathway, termed erythropoiesis, is shown in Figure 1 . Recent studies in mice suggest alternate routes for HSPC differentiation whereby erythroid-and megakaryocytic (platelet-producing cells)-lineage commitment occurs earlier in the hematopoietic hierarchy than previously realized 5, 6 . Other new studies in mice suggest that multipotent and lineage-committed progenitors, rather than hematopoietic stem cells (HSCs), may produce differentiated blood cells under steady-state conditions 7 . Whether this is true in humans remains to be established, but these findings suggest that native erythropoiesis may occur, not through one series of fixed differentiation steps, but rather through multiple pathways that are regulated at the level of lineage commitment and differentiation. This complexity and deviation from standard models of hematopoiesis is important to bear in mind when considering the pathophysiology of various forms of anemia and emerging therapies.
The maturation of lineage-committed erythroid precursors is characterized by reduced proliferative capacity, characteristic morphological changes, and massive accumulation of Hb, the major blood oxygen transporter (Fig. 1) . Because Hb is an iron-containing protein, erythropoiesis is linked to and dependent on physiological pathways that mediate iron absorption and utilization. Numerous cytokines stimulate erythropoiesis, the most clinically important one being erythropoietin (EPO). Evidence suggests that inhibitory cytokines also regulate RBC production in vivo [8] [9] [10] .
To maintain appropriate blood Hb levels, homeostatic mechanisms sense tissue oxygenation and adjust RBC production accordingly. In healthy individuals, steady-state erythropoietic output balances RBC turnover. Anemia, which ensues when homeostatic mechanisms go awry, is caused by three basic problems affecting RBCs: reduced production, increased destruction (hemolysis), or loss (hemorrhage). The associated defects can either be intrinsic or extrinsic to RBCs (or their precursors). Several prevalent causes of anemia, such as dietary iron deficiency, malaria, and other infectious diseases 1 are not dis-may be reduced translation of GATA1 mRNA, which encodes an essential erythroid transcription factor 13, 14 . Most RBC-intrinsic forms of anemia associated with hemolysis are caused by mutations that inhibit the production or function of three major classes of proteins: glycolytic or hexose monophosophate shunt enzymes (as in glucose-6-phosphate dehydrogenase deficiency) 15 , RBC membrane components (as in hereditary spherocytosis) 16 , and Hb (as in sickle cell disease (SCD) and the thalassemia syndromes) 2 . Among these, SCD and b-thalassemia are particularly common and debilitating, affecting millions of individuals worldwide 1, 2 . Recent advances into the pathophysiology of these Hb disorders, mechanisms of globin-family gene expression, and tools for genetic manipulation have elucidated new therapeutic approaches, thereby attracting considerable attention from both academia and industry. cussed further in this review. Rather, we focus on both common and rare forms of anemia for which therapeutic approaches are emerging through exciting new discoveries in erythroid biology.
RBC-intrinsic disorders.
Most forms of anemia within this class are monogenic disorders caused by inherited mutations. Salient examples are discussed here, with greater details and more comprehensive summaries provided by numerous textbooks (for example, ref. 11). Diamond-Blackfan anemia (DBA) is a rare, inherited anemia characterized by developmental anomalies and decreased RBC precursors (hypoplastic anemia). Most DBA-affected people have autosomaldominant mutations in one of at least 12 genes encoding ribosomal protein (RPs) 12 . How haploinsufficiency of different RP-encoding genes causes anemia is unknown, although one common mechanism give rise to the multipotent common myeloid progenitor (CMP) and common lymphoid progenitor (CLP). The CMP then gives rise to megakaryocyte-erythroid progenitors (MEPs) and granulocyte-macrophage progenitors (GMPs). The maturation of lineage-committed erythroid progenitors is shown on the left side. The earliest progenitor, burst-forming unit erythroid (BFU-E), gives rise to the colony-forming unit erythroid (CFU-E). These two progenitors are identified by colony assays. The CFU-E differentiates into morphologically distinct precursors that undergo progressive maturation: proerythroblasts (ProE), basophilic erythroblasts (BasoE), polychromatic erythroblasts (PolyE), and orthochromatic erythroblasts (OrthoE). OrthoE enucleate to produce reticulocytes (Retic) that are released into the circulation and mature further into RBCs. EPO promotes the survival and proliferation of multiple erythroid progenitors and precursors from late BFU-E to basophilic erythroblast stages 113 .
Debbie Maizels/Nature Publishing Group guidelines for the use of EPO as a therapy for people with CKD and other anemias, including its benefits and potential toxicities (http:// kdigo.org/home/guidelines/anemia-in-ckd/) 24 . Overall, the availability of recombinant EPO and its derivatives has had an enormous positive effect on many patients with CKD. However, some individuals with CKD are EPO refractory 27 , requiring enormous doses or alternative therapies, which are discussed below.
Anemia of inflammation.
Inflammation-associated suppression of RBC production contributes substantially to the worldwide burden of anemia 30, 31 . This anemia of inflammation occurs simultaneously with chronic infectious diseases, autoimmune or rheumatologic disorders, Pathophysiology of the major hemoglobinopathies. The adult form of hemoglobin (HbA) is a heterotetramer consisting of two globin protein subunits, a-and b-globin, each encoded by separate genes and bound to a heme prosthetic group. b-thalassemia is caused by mutations that inhibit the production of b-globin polypeptides 17 . Consequently, free a-globin molecules form insoluble aggregates that damage and destroy erythroid precursors in a process termed ineffective erythropoiesis. In this way, b-thalassemia resembles other diseases associated with unstable proteins, including a1-antitrypsin deficiency, Wilson disease, and some neurodegenerative disorders 18 . Free a-globin interacts with various protein quality-control pathways. For example, excess a-globin chains are eliminated by ubiquitin-mediated proteolysis and autophagy 18 . A recent study suggests that excess a-globin binds and sequesters the molecular chaperone HSP70 in the cytoplasm, which in turn destabilizes GATA1, altering gene expression and contributing to ineffective erythropoiesis 19 . In b-thalassemia, ineffective erythropoiesis drives EPO production, which, in a vicious cycle, stimulates ineffective erythropoiesis further. Consequently, massive expansion of delayed and dying erythroid precursors in blood-forming tissues cause bone defects, organomegaly, and metabolic abnormalities 17 . In addition, free a-globin within mature, circulating RBCs induces their hemolysis. Thus, b-thalassemia causes both reduced production and accelerated destruction of RBCs.
In SCD, a single amino acid substitution in the b-globin protein induces deoxygenated HbA tetramers to form rigid polymers within RBCs, causing their deformation into sickle-shaped morphology 20 . Intrinsic alterations in rheology, as well as secondary effects on endothelium, inflammatory cells and plasma proteins, promote the adherence of sickled RBCs to each other and to the inner lining of small blood vessels, causing vaso-occlusion and tissue hypoxia. The clinical consequences of this pathophysiology, termed vaso-occlusive crisis (VOC), include pain crisis, respiratory insufficiency (acute chest syndrome), and strokes 21 .
In SCD and other hemolytic disorders, circulating free Hb released by damaged RBCs degrades the vasodilator nitric oxide 22, 23 . In addition, Hb releases free heme, which activates neutrophils through multiple mechanisms 22 . The resultant inflammatory and vasoconstricting processes are believed to promote disease pathophysiology. Thus, manipulation of haptoglobin and hemopexin, endogenous plasma proteins that scavenge circulating Hb and heme, respectively, may have therapeutic potential.
Severe forms of SCD and b-thalassemia are treated with either regular or intermittent RBC transfusions and supportive care 17, 20, 24 . In many regions of the world, RBC donor availability and high risk for transmission of infectious diseases limits blood transfusion therapy. Moreover, chronic RBC transfusions cause iron overload with damage to numerous organs. Successful stem cell transplantation is curative for SCD and b-thalassemia, but is also limited by toxicities and donor availability 25 . Thus, new treatments for these major Hb disorders are desperately needed.
Anemia of chronic kidney disease (CKD)
. EPO binds the EPO receptor (EpoR) on hematopoietic progenitors to initiate a series of signaling events that promote erythroid differentiation, survival, and proliferation 3, 26 (Fig. 2) . The kidney is the major physiological source of EPO 27, 28 . Consequently, chronic kidney disease (CKD) is associated with EPO deficiency and anemia caused by decreased RBC production. In addition, CKD is a proinflammatory state associated with the production of numerous cytokines that damage or destroy erythroid precursors directly, or that reduce iron availability for erythropoiesis 27, 28 . Hundreds of millions of people worldwide are affected by CKD, many of whom are EPO deficient 29 . Numerous review articles provide Stimulatory and inhibitory pathways regulating erythropoiesis. EPO engages EpoR on erythroid precursors to activate a signaling cascade that begins with JAK2, thereby facilitating survival and proliferation. EPO mRNA is normally secreted from a subset of adult kidney cells and its expression is regulated by HIF family members. Hypoxia stabilizes HIF proteins by inhibiting the activity of prolyl hydroxylase enzymes (PHD) that stimulate HIF degradation. Pharmacological prolyl hydroxylase inhibitors (PHIs) stabilize HIF to stimulate EPO production, not only in the kidney as shown, but also in the liver of anephric patients (not shown). Growth differentiation factor 11 (GDF11) may negatively regulate erythropoiesis by engaging transforming growth factor-b receptors and is blocked by activin-receptor traps, including sotatercept and ACE-536. The physiological source of GDF11 is currently unknown.
Debbie Maizels/Nature Publishing Group called sotatercept was generated to treat osteoporosis. Development of this product was based on preclinical studies implicating activin signaling in bone homeostasis 41, 42 . To the surprise of clinical investigators, sotatercept also induced dramatic increases in both Hb and RBC counts in healthy human subjects 42 . Sotatercept and a modified version (ACE-536) appear to stimulate erythropoiesis by blocking the activity of the bone morphogenetic protein family member GDF11 (refs. 43,44) (Fig. 2) . These agents act independently of EPO and, in preclinical models, they stimulate erythropoiesis in several EPO-refractory anemic states, including b-thalassemia and MDS 43, 44 . Further studies are needed to better understand the role of GDF11 in normal erythropoiesis and various anemias 8 . For example, even though erythroid precursors themselves may be a source of GDF11, the most important physiologic sources of this cytokine are unknown. In addition, the stages of erythropoiesis targeted by GDF11, the precise receptors through which it acts, and the mechanisms through which it blocks erythroid maturation remain to be defined. Recent work in mice suggests that GDF11 may also inhibit aging of various tissues such as the heart, skeletal muscle, and brain [45] [46] [47] [48] . Whether inhibiting GDF11 through receptor traps or other means will accelerate tissue aging must be investigated. Regardless, this approach holds promise for treating anemia (particularly in patients with EPO-refractory states) and clinical trials for this use are underway (NCT01736683, NCT01464164, NCT01999582; https://ash.confex.com/ ash/2014/webprogram/Paper73847.html).
Other strategies. Ongoing research has revealed additional pathways that stimulate erythropoiesis. Recent work has shown that polymeric human IgA1 interacts with transferrin receptor 1 to augment EpoR signaling 49 . During the anemia of inflammation, hepcidin-induced iron restriction (discussed below) inhibits the activity of aconitases, iron-dependent enzymes that convert citrate to isocitrate as part of the tricarboxylic acid cycle. Isocitrate is a precursor in the production of ATP, reducing equivalents, and heme, and it may also suppress inflammatory signaling. In a rodent model for the anemia of chronic disease, administration of isocitrate bypassed aconitase deficiency to relieve some erythropoietic defects 50 . These interesting findings may illustrate new approaches for treating anemia, although further investigation is required.
Fetal hemoglobin induction for β-hemoglobinopathies Targeting relevant transcription factors. Strategies to replace mutated or deficient adult b-globin are of potential benefit for SCD and b-thalassemia, respectively. Fetal Hb (HbF) is composed of two b-like g-globin chains and two a-globin chains. HbF is the major form of Hb expressed during gestation and supports oxygen transport in the fetus. Around birth, g-globin production from two genes (HBG1 and HBG2) declines, whereas transcription of the nearby HBB gene encoding adult type b-globin increases gradually (Fig. 3a) . This 'hemoglobin switch' is typically complete at around 6 months of age, which explains why people with b-thalassemia and SCD begin to manifest major symptoms in late infancy 51 . Rare individuals carry mutations in regulatory regions of the b-globin locus that inhibit the g-to-b switch, resulting in increased HbF throughout life, a benign condition known as hereditary persistence of fetal hemoglobin (HPFH) 52 . Remarkably, individuals with concomitant HPFH and b-thalassemia or SCD mutations exhibit reduced disease severity and in some cases are entirely asymptomatic 51, 53, 54 . These clinical observations indicate that preventing or reversing the g-to-b-globin switch through drugs or genetic manipulation could be a powerful approach for treating SCD and b-thalassemia. Individuals with isolated HPFH are asymptomatic, demonstrating that the persistent high levels of HbF in adults have no adverse consequences. and other systemic illnesses. The pathophysiology derives largely from the actions of proinflammatory cytokines, which stimulate hepcidin production to inhibit iron absorption and utilization (see below), block the differentiation of erythroid precursors or progenitors directly, and inhibit the responsiveness of erythroid precursors and progenitors to EPO 30, 32, 33 .
Anemia of cancer.
Approximately 40% of people with cancer have symptomatic anemia, which can limit their quality of life and contribute to morbidity 34 . Causes of cancer-associated anemia include chemotherapy-induced myelosuppression and the production of inhibitory cytokines 9 . Myelodysplastic syndrome (MDS), a common disorder in older individuals, is associated with hematopoietic cell-intrinsic defects in RBC production 35 . This anemia sometimes improves with the administration of EPO and/or chemotherapeutic agents. However, responses to these treatments are often transient, and thus many individuals with MDS-associated anemia eventually require RBC transfusions.
Stimulating erythropoiesis
Modulating EPO receptor signaling. EPO and its long-acting analogs are widely used to support erythropoiesis in patients with CKD, cancer, and other forms of anemia associated with insufficient endogenous production of this cytokine 27 . Theoretically, alternative approaches that stimulate EpoR may have additional clinical benefits when compared to EPO-based therapies, including oral bioavailability and/or additional erythropoietic activities 36 . The long-acting pegylated peptide peginasatide, which bears no structural resemblance to EPO, activates EpoR signaling potently to stimulate erythropoiesis 36 . This agent was briefly used clinically to treat the anemia of CKD as well as a rare form of anemia caused by endogenous production of EPO-neutralizing antibodies 37, 38 . However, peginasatide was removed from the market after it was found to cause an unacceptably high rate of anaphylaxis 39 .
EPO is synthesized mainly by a group of poorly defined kidney cells that are capable of sensing hypoxia (Fig. 2) . However, other tissues (predominantly the liver) provide an alternative endogenous source of EPO that can be stimulated pharmacologically. Transcription of the EPO gene is activated by low oxygen tension through the hypoxiainducible family of transcription factors (HIFs) 40 . Under normoxic conditions, prolyl hydroxylase enzymes hydroxylate HIFs, which targets them for proteasomal degradation. The use of prolyl hydroxylase inhibitors (PHIs) has thus emerged as a promising approach to stimulate HIF activity and thereby increase endogenous EPO production 27 (Fig. 2) . Clinical trials of orally administered PHIs in patients with CKD and other EPO-dependent anemias are underway and early results are promising 28 . However, HIFs regulate the expression of many genes besides EPO, a fact that has both positive and negative implications for treating anemia 40 . For example, HIFs may alter iron distribution to increase its bioavailability for erythropoiesis during chronic inflammatory states, such as CKD and cancer. In contrast, HIFs stimulate angiogenesis, which could theoretically promote tumor growth. Moreover, some PHIs are linked to clinically adverse effects such as liver necrosis 27 . Newer tissue-specific and isoform-selective PHIs are being investigated and may reduce some toxicities 28 . Overall, PHIs represent promising erythropoietic agents with potentially widespread applications.
Suppressing GDF11. It has been known for some time that erythroid precursors are subject to negative regulation of maturation and/or survival by cytokines, but such pathways have not yet been exploited therapeutically 9, 10 . Recently, a ligand trap for the activin receptor type IIA pression of Bcl11a by gene ablation raised HbF to therapeutic levels with minimal effects on other erythroid genes, thereby reducing clinical complications 56, 58, 59 . These studies identify BCL11A as a key therapeutic target for HbF induction. However, approaches to suppress BCL11A in humans are challenging for two important reasons. First, transcription factors are notoriously difficult to inhibit with small molecules 53 . Second, BCL11A has essential functions in non-erythroid cells such as lymphocytes and neurons 53 . Repression of BCL11A through RNAi or gene editing in HSCs may circumvent some of these problems (see Box 1 on gene editing strategies) 60 . Recent work has identified an erythroid-specific BCL11A enhancer and cis-elements within the human b-globin locus that are bound by the BCL11A protein 52, 57 . These DNA regions may be useful targets for gene-editing approaches to raise HbF by inhibiting BCL11A or its activity specifically at the b-globin locus. In addition, BCL11A has been shown to function within large protein complexes that include epigenetic modifier enzymes (discussed below), which may represent more tractable (albeit less specific) drug targets 53, 56, 61 .
Additional molecular targets for HbF induction also exist (Fig. 3b) 53, 62 . For example, common DNA polymorphisms and rare mutations that reduce expression of the MYB gene in erythroid progenitors are associated with elevated HbF [63] [64] [65] [66] . MYB is a transcription factor with pleiotropic roles in hematopoiesis, raising concern that its manipulation may be toxic. However, studies in mice show that partial Myb suppression can inhibit leukemogenesis while sparing normal hematopoiesis, thereby identifying a potential therapeutic range for HbF induction 67 . Rare mutations in the gene encoding the erythroid transcription factor KLF1 have been identified in individuals with elevated HbF, although the extent of induction varies and some KLF1 mutations also cause anemia 53, [68] [69] [70] . The nuclear hormone receptors TR2 and TR4 have also been suggested to regulate g-globin transcription, and overexpression of these factors increased HbF levels and ameliorated clinical symptoms in a mouse model of SCD 62, 71 . As with BCL11A, these transcription factors pose challenges as pharmacological targets.
Targeting epigenetic enzymes.
Rather than targeting transcription factors themselves, it may be more feasible to inhibit their associated enzymes that regulate gene expression by modifying histones and other nuclear proteins. The histone deacetylases (HDACs) are suggested to regulate HbF expression through the modification of chromatin, and these nuclear proteins physically associate with many of the transcription factors that regulate HbF 51 . Chemical and RNAi screens showed that inhibiting HDAC1 and HDAC2 induces HbF in primary human erythroblasts 72 . In addition, inhibitors of LSD1/KDM1A, a flavin-dependent monoamine oxidase that demethylates lysines 4 and 9 in histone H3, including the antidepressant tranylcypromine, were shown to induce HbF production in primary human cells and animal models 73 . However, other studies show that LSD1/KDM1A inhibition can also impair normal erythropoiesis, raising concerns about the viability of this therapeutic target 61 . More generally, because epigenetic enzymes are expressed ubiquitously and have multifaceted functions, their long-term inhibition may be toxic, particularly in hemoglobinopathy patients for whom therapies are most effective when initiated early in childhood and continued throughout life. Of note, the potential of small-molecule inhibitors of HDACs and LSD1/KDM1A as anti-cancer agents is being studied in numerous clinical trials. HbF quantification, which is simple, inexpensive, and does not require extra blood sampling, should be incorporated into these studies. Although the results might be confounded by intercurrent malignancy, medications and other factors, such studies could provide valuable information for assessing the utility of these drugs and their associated molecular pathways for HbF induction in humans.
More than 30 years ago, hydroxyurea was found to induce HbF production and alleviate symptoms and organ damage in patients with SCD, through mechanisms that remain incompletely understood 55 . Recent guidelines from the National Institutes of Health recommend that routine hydroxyurea treatment, beginning at the age of 9 months and regardless of symptoms, be considered for all people treated for SCD (http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-diseaseguidelines). However, hydroxyurea induces only modest HbF expression and is not a cure for SCD. Thus, there has been a longstanding search for better HbF-inducing agents 53 .
New approaches to promote HbF production have emerged from recent studies investigating the mechanisms of Hb switching. Genome-wide association and functional follow-up studies of HbF levels identified the multi-zinc finger transcription factor, BCL11A, to be a key repressor of g-globin expression and a physiological mediator of the g-to-b switch (Fig. 3) 56 . Indeed, some HPFH mutations within the b-globin gene cluster may promote g-globin gene transcription by preventing BCL11A from binding to its target regions 52, 57 . Subsequent work in mouse models for SCD demonstrated that sup- Debbie Maizels/Nature Publishing Group hydroxylase inhibitors, discussed earlier, may alleviate anemia not only by enhancing endogenous EPO production, but also by reducing hepcidin levels to stimulate the uptake of dietary iron and its release from reticulendothelial stores. For two main reasons, iron overload is a major toxicity in b-thalassemia, and to a lesser extent, in SCD and other conditions requiring regular transfusions. First, RBC transfusion therapy increases the iron burden and no physiological mechanisms exist for its elimination 85, 88 . Second, accumulation of erythroid precursors, particularly with b-thalOther strategies for treating hemoglobinopathies Treatment of ineffective erythropoiesis in β-thalassemia. In b-thalassemia, ineffective erythropoiesis combined with elevated EPO causes pathological expansion of immature, damaged erythroid precursors. Thus, chemical inhibition of JAK2, which mediates the proliferative effects of EPO, reduces splenomegaly and improves anemia in b-thalassemic mice 74 . Further studies to demonstrate the safety and efficacy of JAK2 inhibition in people with b-thalassemia are required 75 . As noted earlier, inhibition of GDF11 signaling via ligand traps such as sotatercept or ACE-536 may reduce ineffective erythropoiesis and raise RBC production in b-thalassemia 43 . Finally, new therapies aimed at manipulating protein quality-control mechanisms to enhance degradation of free a-globin or reduce its interaction with HSP70 may be useful for treating b-thalassemia 19 .
Reducing inflammation and sickle cell formation in SCD. Numerous studies seek to better define and inhibit inflammation in SCD. For example, blockade of the adhesion receptors P-and E-selectins, may reduce VOC 76, 77 . Other anti-inflammatory agents, such as intravenous immunoglobulin and those that block the CXC chemokine receptor CXCR2 have shown promise in model systems 78, 79 . Additional approaches to reduce inflammation are ongoing 21 . A subset of inflammatory cells known as iNKT cells may contribute substantially to the ischemicreperfusion injury thought to underlie VOC 80 . Mice and humans with SCD have increased numbers of iNKT cells, and blockade of these cells appears to be safe and potentially effective for preventing VOC and its associated complications 81 .
Only deoxygenated HbS is capable of sickling. This supports the use of inhaled oxygen as a powerful short-term therapy for VOC, although long-term and excessive administration of oxygen to individuals with SCD can suppress EPO production and erythropoietic drive 82 . A potentially more effective long-term approach is to use molecules that bind HbS, increase its affinity for oxygen, and thereby prevent polymerization and sickling 83, 84 . 5-hydroxymethyl-2-furfural is an example of one such molecule. More potent and orally-bioavailable derivatives are under clinical investigation (NCT02285088, NCT01987908) 83 .
Manipulating iron absorption and distribution. Recent insights into the physiological regulation of iron homeostasis are relevant to understanding and treating many forms of anemia [85] [86] [87] [88] (Fig. 4) . The membrane transporter ferroportin stimulates uptake of iron by intestinal epithelial cells and egress of iron from macrophages. Hepcidin, a small peptide secreted by the liver, binds ferroportin and stimulates its degradation, causing reduced intestinal absorption of iron and its accumulation within the reticuloendothelial system.
Inflammatory cytokines, such as interleukin-6, stimulate hepcidin production, which contributes to the anemia of chronic disease and inflammation by reducing iron availability for erythropoiesis. Prolyl
Box 1 Genome editing strategies
With the advent of novel genome editing approaches using zinc fingers, transcription activator-like effector nucleases (TALENs), homing endonucleases and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas), the potential for endogenous gene correction has become a reality 115, 116 . Each of these technological advances works in a slightly different manner to create precisely engineered DNA breaks that promote insertion/deletion (indel) mutations via nonhomologous end-joining DNA repair pathways or that are faithfully repaired by homologous recombination with exogenous DNA templates 116 . Pioneering work has demonstrated that it is possible to modify endogenous genes in primary human HSPCs, including the inactivation of the HIV co-receptor CCR5 which may used to treat acquired immune deficiency syndrome and restored expression of a defective IL2RG gene for treatment of X-linked severe combined immunodeficiency [117] [118] [119] . Current challenges for genome editing of HSPCs include optimizing the delivery of gene-editing tools, improving the efficiency of introducing targeted modifications of interest, and avoiding the creation of potentially harmful off-target mutations. Figure 4 Regulation of iron homeostasis. Hepcidin-encoding gene transcription in hepatocytes is regulated by BMP6, BMP6 receptors, the coreceptor hemojuvelin (HJV) and inflammatory cytokines such as interleukin 6 (not shown). TMPRSS6 cleaves HJV to inhibit hepcidin production. Secreted hepcidin (green circles) binds the iron transporter ferroportin and stimulates its degradation, resulting in decreased intestinal iron (orange circles) absorption and iron accumulation in reticuloendothelial cells. During ineffective erythropoiesis in b-thalassemia and other disorders, accumulated bone marrow erythroid precursors release erythroferrone (purple hexagon) and GDF15 (blue square), which suppress liver hepcidin production, causing inappropriate iron absorption and release of iron from reticuloendothelial cells.
Debbie Maizels/Nature Publishing Group b-thalassemia. Normalizing the body's iron burden also appears to reduce ineffective erythropoiesis in b-thalassemic mouse models, suggesting an added benefit to inhibiting iron uptake 93, 94 .
Manipulating the genome to treat congenital anemias. Congenital forms of anemia are prevalent worldwide, particularly the b-Hb disorders 1,2 . Because b-thalassemia and SCD are well-characterized disorders caused by monogenic mutations, they are amenable to cure by gene-replacement therapy (Fig. 5) . In this approach, HSPCs are removed from the patient, modified to express a b-like globin protein in erythroid precursors and then reinfused 95 . In principle, the modified HSCs will reconstitute the hematopoietic system, thereby producing normal, gene-corrected RBCs. The major challenges to this approach are requirements for genetic correction of a large proportion of HSCs, high-level engraftment of the corrected cells after transplantation, and sufficient production of the restored b-like globin protein.
The earliest trials of hematopoietic cell gene therapy focused on immune disorders, such as severe combined immunodeficiency caused by defects of the interleukin-2 receptor g chain 95 . This disorder is tractable for gene therapy because its amelioration requires relatively modest expression levels of the deficient protein, and because gene-corrected lymphocytes have a strong survival advantage in vivo. In contrast, norassemia-associated ineffective erythropoiesis, release erythroferrone and GDF15 (refs. 86, 87) , which are believed to act on the liver to suppress hepcidin production (Fig. 4) . Consequently, dietary iron absorption increases and iron storage in macrophages is suppressed. Through both mechanisms, toxic free iron accumulates in the blood and various tissues including the liver, pancreas, and heart. Several iron chelators are available to treat iron overload 85 . However, these agents are somewhat nonspecific, have toxicities, and may not be fully effective, thereby prompting searches for additional therapies.
TMPRSS6 is a serine protease that cleaves hemojuvelin (HJV), a coreceptor for BMP6. Therefore, suppression of TMPRSS6 stimulates hepcidin production, which may be exploited therapeutically to reduce iron overload in hemoglobinopathy patients 89, 90 . Direct administration of hepcidin would produce similar beneficial effects, but this peptide is short lived in vivo 88 . Thus, efforts are underway to produce hepcidin-like molecules with increased stability. One such group of molecules, termed minihepcidins, reduce iron overload in animal models 91, 92 . Ongoing studies of iron metabolism are likely to identify additional approaches for treating iron overload (or deficiency). For example, further insights into the mechanisms of erythroid erythroferrone synthesis and action should identify new strategies to modulate hepcidin, which would be of particular benefit to people with ineffective erythropoiesis, including those with Debbie Maizels/Nature Publishing Group
HSPCs will soon be refined to the point at which gene editing can be used safely and efficiently to treat numerous blood disorders, including those that affect RBC production and/or survival.
Conclusions and future directions
Recent scientific discoveries have increased our understanding of erythropoiesis and associated disorders, elucidating new therapeutic opportunities. These include the identification of GDF11 as a negative regulator of erythropoiesis and discoveries of numerous enzymes, cytokines, and hormones that regulate iron metabolism. In addition, technological advances, such as refined lentiviral vectors and gene-editing approaches raise the possibility that genetic defects causing anemia can be alleviated or repaired precisely for long-lasting disease correction. However, major challenges remain. Further improvements in stimulating erythropoiesis pharmacologically rely on better understanding the roles of positively and negatively acting cytokines on this process and the potential toxic effects of these molecules on bystander tissues. Manipulating newly identified transcriptional regulators of HbF production, such as BCL11A and histone-modifying enzymes, remains challenging and the full spectrum of side effects from targeting these molecules is unknown 53 . Importantly, much of our knowledge regarding human hematopoiesis, including erythroid development, is based on mouse models 4, 109 . Although these studies are valuable, fundamental differences between mouse and human erythropoiesis are becoming more apparent [110] [111] [112] . Thus, new approaches for studying human hematopoiesis are essential for developing new therapeutics 4, 109 .
Methods for translating and prioritizing major technological and scientific advances into meaningful global therapies must be considered carefully. Technologically sophisticated, expensive approaches such as gene therapy or biologic drug infusions are not feasible for large numbers of people who live in developing countries where SCD and b-thalassemia are common 1,2 . Thus, balanced perspectives and approaches are required. Continued efforts must be applied to advance the best available therapies into widespread use, such as the use of hydroxyurea for SCD, and to develop improved oral agents that can be manufactured inexpensively. Moreover, even basic interventions such as regular transfusions and iron chelation can have a considerable benefit for individuals with anemia when used appropriately and regularly. Thus, efforts to improve the treatment of these disorders must balance the application of advanced technologies with current needs to deliver optimal therapies to the greatest numbers of people. Close collaboration between basic scientists, clinical investigators, and front-line clinicians is required to achieve these goals. Because anemia contributes considerably to the worldwide burden of disease, it is likely that our rapidly advancing ability to treat these disorders will have a profound impact on the lives of affected individuals and their families. mal b-globin expression must be restored to high levels for alleviation of the symptoms of SCD or b-thalassemia (the normal RBC Hb concentration is 35 g/dL).
Painstaking work over many years has led to the development of HIV1-based lentiviral vectors that can infect human HSCs and support high-level, erythroid-specific expression of b-like globins 96, 97 . Most vectors encode a mutant version of b-globin that prevents sickle Hb polymerization or native g-globin, which also has this property 95 . On the basis of this work, a clinical trial was initiated for b-thalassemia and one treated patient became transfusion independent 98 . However, a predominant hematopoietic clone was detected with aberrant expression of the HMGA2 gene near the site of lentiviral integration 98 . This finding was concerning, given the leukemogenic effects of vector-induced activation of oncogenes noted in other gene therapy trials 95, 99, 100 . New generations of vectors are now being designed to reduce the tendency of integrated viral vectors to activate nearby genes and also to further increase b-like globin expression. Early clinical trial results in additional b-thalassemia patients treated with these improved vectors are promising (https://ash. confex.com/ash/2014/webprogram/Paper67341.html).
Innovative new strategies for gene therapy of SCD and b-thalassemia may circumvent the requirements for high-level expression of vectorencoded b-like globin. For example, suppression of BCL11A expression by short hairpin RNAs (shRNAs) induces g-globin expression in adult human erythroblasts 56, 60 . This represents a potential gene therapy strategy for b-hemoglobinopathies, either alone or in combination with b-like globin gene replacement, although it may be important to suppress BCL11A selectively, because the protein is required for lymphopoiesis 53 . Recently, a new strategy for stimulating HbF production in adult erythroblasts was demonstrated by expressing zinc fingers fused to protein dimerization domains, which bind specific DNA sequences and each other to promote physical interaction ('looping') between g-globin and an upstream enhancer termed the locus control region 101 . Further work is necessary to ensure that this approach does not interfere with normal erythropoiesis or globin production in vivo.
The potential for using gene therapy to treat erythroid disorders extends beyond the b-hemoglobinopathies. Other monogenic erythroid diseases, particularly those where allogeneic hematopoietic transplantation is used for treatment, may be ideal targets (Fig. 5) . For example, gene therapy has been investigated for DBA, but this would require separate vectors for each different form of the disease, which is caused by mutations in one of at least 12 RP-encoding genes 102 . It was recently shown that DBA can also be caused by mutations in GATA1 (ref. 14) . Moreover, GATA1 mRNA translation was impaired selectively in erythroblasts of DBA-affected patients with RP-encoding gene mutations, and enforced expression of GATA1 in these cells partly rescued their defective erythropoiesis 13 . Thus, viral vector encoded GATA1 may represent a more versatile gene therapy approach for multiple forms of DBA, including forms in which GATA1-and RP-encoding genes are mutated. Other erythroid diseases, such as congenital erythropoietic porphyria, in which toxic porphyrin metabolites produced by erythroid precursors cause multisystemic illness, and red cell enzyme disorders, including severe forms of glucose 6-phosphate dehydrogenase and pyruvate kinase deficiency, also show promise for gene therapy correction [103] [104] [105] [106] .
Until recently, all hematopoietic gene therapy approaches relied on the introduction of exogenous genetic material, mainly via viral vectors. Recent developments in the field of genome editing offer exciting new approaches (Box 1). Both b-thalassemia and SCD mutations have been corrected by gene editing in pluripotent stem cells 107, 108 . It may also be possible to treat these disorders by using a similar approach to disrupt BCL11A expression in erythroid cells, thereby de-repressing g-globin synthesis. It is likely that our ability to modify resident genes within
